Related Experiment Video
Updated: Oct 28, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Cognitive level and rate of change in relapsing and progressive multiple sclerosis: a single-center retrospective
Tatsuya Ueno1, Maki Miura1, Tomoka Iwasawa1
1Department of Neurology, Aomori Prefectural Central Hospital, 2-1-1 Higashi-tsukurimichi, Aomori, 030-8553, Japan.
Background:
Although secondary and primary progressive multiple sclerosis (MS) are associated with poorer cross-sectional cognition than relapsing MS, whether decline is faster remains uncertain. We examined associations of phenotype with cognitive performance and annual change.
Methods:
In this single-center retrospective study, 37 patients with MS underwent serial assessment using the Symbol Digit Modalities Test (SDMT), Japanese version of the Montreal Cognitive Assessment (MoCA-J), and Frontal Assessment Battery (FAB) (161 observations; 144 for SDMT). Phenotype at the first assessment was retained throughout follow-up. Linear mixed-effects models included random intercepts and slopes and were adjusted for baseline age, sex, education, and Expanded Disability Status Scale (EDSS) score; time was mean-centered.
Results:
At baseline, 26 patients had relapsing and 11 had progressive disease. Mean follow-up was 4.2 years. The progressive group scored lower than the relapsing group: SDMT, -14.18 points (95% confidence interval [CI]: -25.00, -3.35); MoCA-J, -3.25 (-5.65, -0.85); FAB, -1.80 (-3.18, -0.43). Phenotype-by-time interactions were non-significant (SDMT: -0.87 points per year [95% CI: -2.03, 0.29]; MoCA-J: -0.24 [-0.54, 0.06]; FAB: -0.14 [-0.35, 0.08]).
Conclusion:
Progressive MS was associated with lower cognitive performance after adjustment for baseline EDSS score, without evidence of different rates of change. Lower MoCA-J and FAB scores in progressive MS have rarely been documented in Japanese patients. Larger cohorts with longer follow-up are needed to determine whether rates differ.
Related Concept Videos
Multiple Sclerosis l: Introduction
Alzheimer Disease l: Introduction
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Bioavailability Study Design: Single Versus Multiple Dose Studies
